Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NMTC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — CFO Ronald McClurg is retiring effective June 30, 2026, triggering a leadership transition at the financial helm.
NeuroOne CFO Ronald McClurg to retire; COO Christopher Volker promoted to CFO
Filed April 30, 2026 · Period ending April 24, 2026 · ~1 min read
Key Changes
-
high
CFO Ronald McClurg retiring effective June 30, 2026, will stay as Senior Advisor through year-end to ensure smooth transition of financial leadership duties.
Item 5.02 verify on EDGAR → -
high
COO Christopher Volker promoted to CFO effective July 1, 2026, bringing medtech finance experience from Abbott, Cardiovascular Systems, and St. Jude Medical including M&A and strategic planning expertise.
Item 5.02 verify on EDGAR → -
medium
Volker's base salary increased to $350,000 upon CFO appointment, with other employment terms unchanged.
Item 5.02 verify on EDGAR → -
medium
McClurg signed Transition and Release Agreement dated April 28, 2026, providing continued salary and benefits through December 31, 2026 in exchange for general release of claims and restrictive covenants.
Item 5.02, Exhibit 10.1 verify on EDGAR →
Summary
NeuroOne Medical Technologies announced a planned CFO transition with Ronald McClurg retiring after June 30, 2026. McClurg will remain as Senior Advisor through year-end to facilitate handoff of financial responsibilities. The company is promoting from within, elevating COO Christopher Volker to CFO effective July 1, 2026. Volker brings relevant medtech industry experience from major players including Abbott and St.
Jude Medical, with a background in senior finance roles and investment banking focused on M&A and strategic planning. His base salary increases to $350,000 in the new role. The internal promotion suggests continuity in financial strategy and operations. Retail investors should monitor the Q2 and Q3 earnings calls for signs of smooth transition in financial reporting quality and strategic messaging. Watch whether Volker maintains or adjusts the company's capital allocation priorities and how he communicates NeuroOne's path to profitability or funding needs during his first quarters as CFO.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 24, 2026, Ronald McClurg notified NeuroOne Medical Technologies Corporation (the “Company”) of his intention to retire as the Company’s Chief Financial Officer. The effective date of Mr. McClurg’s retirement as Chief Financial Officer will be June 30, 2026. Following his retirement as an officer, Mr. McClurg will remain employed by the Company as a Senior Advisor, to ensure a smooth transition of duties, until December 31, 2026 (the “Retirement Date”).
CFO Ronald McClurg announced his retirement effective June 30, 2026. He will transition to a Senior Advisor role through December 31, 2026 to facilitate continuity. The company has entered into a Transition and Release Agreement providing continued salary and benefits through year-end in exchange for a general release of claims.
Added in current filing · verify on EDGAR →
Mr. Volker’s base salary will be increased to $350,000 in connection with his appointment as Chief Financial Officer, but the other compensatory and material terms of Mr. Volker’s employment with the Company will remain unchanged.
Christopher Volker's base salary will increase to $350,000 upon assuming the CFO role, with all other employment terms remaining the same.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Transition and Release Agreement, by and between the Company and Ronald McClurg, dated April 28, 2026
The company entered into a Transition and Release Agreement with Ronald McClurg on April 28, 2026.Such agreements typically involve executive departures, severance arrangements, and mutual release of claims.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify